Spooner C H, Saunders L D, Rowe B H
Institute of Health Economics, No. 710, 10665 Jasper Avenue, Edmonton, Alberta, Canada, T5J 3S9.
Cochrane Database Syst Rev. 2000;2002(2):CD001183. doi: 10.1002/14651858.CD001183.
Exercise-induced asthma causes cough, dyspnea, wheeze and chest tightness. Management of focuses on prevention through pharmaco-therapy and alternate strategies. Single use, pre-exercise beta2-agonists and non-steroidal anti-inflammatory agents such as the cromones are the most common treatments.
The objective of this review was to assess the effects of a single dose of nedocromil sodium to prevent exercise-induced bronchoconstriction.
We searched the Cochrane Airways Group trials register, the Cochrane Controlled Trials Register, Current Contents, review articles, textbooks and reference lists of articles. We also contacted the drug manufacturer and primary authors for additional citations.
Randomised trials comparing a single dose of nedocromil sodium with placebo to prevent exercise-induced bronchoconstriction in people over six years of age.
Trial quality assessment and data extraction were conducted independently by two reviewers. Study authors were contacted for confirmation of data.
Twenty randomised controlled trials involving 280 participants were identified. 15-60 min following inhalation of 4 mg nedocromil, the maximum fall in forced expiratory volume in one second due to exercise was improved by 15.6%, (95% CI:13.2 to 18.1) compared to the placebo response. The maximum percentage fall in peak expiratory flow rate was of the same magnitude (weighted mean difference 15.0%; 95% CI 8.3 to 21.6). Nedocromil shortened the time to recover lung normal function from more than 30 minutes with placebo to less than 10 minutes with the drug. The relative magnitude of its effect was greatest in patients with more severe exercise-induced bronchoconstriction (defined as an exercise-induced fall in lung function > 30% from baseline). There were no significant adverse effects reported.
REVIEWER'S CONCLUSIONS: Nedocromil sodium used before exercise appears to reduce the severity and duration of exercise-induced bronchoconstriction. This effect appears to be more pronounced in people with severe exercise-induced bronchoconstriction.
运动诱发性哮喘会导致咳嗽、呼吸困难、喘息和胸闷。其治疗重点在于通过药物治疗和其他策略进行预防。单次使用运动前β2受体激动剂以及色酮类等非甾体抗炎药是最常见的治疗方法。
本综述的目的是评估单剂量奈多罗米钠预防运动诱发性支气管收缩的效果。
我们检索了Cochrane Airways Group试验注册库、Cochrane对照试验注册库、《现刊目次》、综述文章、教科书以及文章的参考文献列表。我们还联系了药品制造商和主要作者以获取更多参考文献。
比较单剂量奈多罗米钠与安慰剂预防6岁以上人群运动诱发性支气管收缩的随机试验。
由两名评价员独立进行试验质量评估和数据提取。联系研究作者以确认数据。
共识别出20项涉及280名参与者的随机对照试验。吸入4毫克奈多罗米后15 - 60分钟,与安慰剂组相比,运动导致的一秒用力呼气量最大降幅改善了15.6%(95%置信区间:13.2至18.1)。呼气峰值流速的最大降幅百分比幅度相同(加权平均差15.0%;95%置信区间8.3至21.6)。奈多罗米将肺功能恢复正常的时间从安慰剂组的30多分钟缩短至用药组的不到10分钟。在运动诱发性支气管收缩更严重(定义为运动导致的肺功能较基线下降>30%)的患者中,其效果的相对幅度最大。未报告显著的不良反应。
运动前使用奈多罗米钠似乎可减轻运动诱发性支气管收缩的严重程度并缩短其持续时间。这种效果在运动诱发性支气管收缩严重的人群中似乎更为明显。